Introduction There is potential value in testing individual response to P2Y12 inhibitors in order to predict ischaemic and bleeding risk in PCI patients. We aimed to:
a) validate the ability of a novel point of care (POC) assay using thrombelastography, TEG6s, to detect changes in ADP-induced whole blood clotting and
b) compare a novel, rapid test parameter, area under the curve at 15 min (AUC15), with the traditional maximum clot amplitude (MA).
Methods 25 participants were included in whom ADP-induced clotting was measured at 4 time points: a) 12 healthy volunteers given 600 mg of clopidogrel; b) 12 patients with ACS given 600 mg of clopidogrel; c) 1 healthy volunteer given 600 mg of clopidogrel on 5 separate occasions.
All samples were tested using traditional TEG5000 and the new point of care TEG6S.
TEG 5000 and TEG 6 s detected changes in ADP–induced clotting. Bland Altman analysis demonstrated a good level of agreement between them [figure 1a].
For TEG6S, correlation between MA & our novel AUC15 was strong for both thrombin and ADP channels [figure 1b] (R=0.867, R=0.936, p<0.001), & the AUC15 result was available on average 13.3 mins earlier.
Conclusions TEG6s is a rapid, easy to use and accurate test of ADP-induced clotting using TEG5000 as a reference. A novel parameter, AUC15, is a viable and time saving option for this POC test.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.